Menu

Biocon

Biocon has added a new national drug code for its insulin biosimilar, the drugmaker recently notified 340B providers.

Biocon Announces New NDC for its Lantus Biosimilar

October 26, 2023 Tom Mirga, Editor at Large 340B Report Views

Indian biopharmaceutical manufacturer Biocon Biologics has notified 340B covered entities about a new national drug code (NDC) for insulin glargine-yfgn, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga

Column: Look to The Senate for 340B Action

Louisiana AG Election to Name Enforcer, Defender of 340B Contract Pharmacy Law